Valeant Must Sell Three Rx Dermatology Drugs To Acquire Dermik and Ortho Dermatologics
This article was originally published in The Pink Sheet Daily
Executive Summary
The Federal Trade Commission requires Valeant to sell BenzaClin and 5FU to Mylan and Refissa to Spear Pharmaceuticals; Valeant also must produce a backup supply of 5FU until Mylan can manufacture the drug commercially.
You may also be interested in...
Valeant’s Latest M&A Gambit Hits Snag With Ista’s Rejection Of $314 Million Buyout Offer
The industry’s third largest ophthalmology company turns down a $6.50-per-share offer, saying the bid grossly undervalues the potential of its pipeline.
Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million
Sanofi divests its U.S and Canadian dermatology business to focus on core areas; Valeant beefs up skin care franchise and adds manufacturing capacity.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.